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Hypogonadism is assumed to be present in sarcoidosis. Nevertheless, a comparison of
circulating sex hormone concentrations of male sarcoidosis patients with those of healthy
men has never been done. Moreover, it remains unknown if hypogonadism may contribute
to a reduced muscle function, exercise intolerance, diminished vitality and depressed
mood in male sarcoidosis patients.
Pulmonary function, muscle function, exercise tolerance, vitality, mood, circulating sex
hormone concentrations and C-reactive protein were assessed in 30 male sarcoidosis
patients and 26 age-matched men with a normal pulmonary function.
On average, patients had a restrictive pulmonary function, worse inspiratory and
quadriceps muscle function, functional exercise intolerance, diminished vitality,
depressed mood and increased systemic inflammation. Moreover, patients had significantly
lower circulating (free) testosterone concentrations, while circulating sex hormone-
binding globulin tended to be lower (p ¼ 0.0515). Circulating gonadotrophin concentra-
tions were comparable. Non-significant relationships were found between sex hormones,
clinical outcomes and C-reactive protein in patients with sarcoidosis.
A significant number of male outpatients with sarcoidosis (46.7%) had low circulating
testosterone concentrations, which was most probably caused by hypogonadotrophism.
The clinical relevance of hypogonadism in male outpatients with sarcoidosis, however,
remains currently unknown. Indeed, poor inspiratory and quadriceps muscle function,Elsevier Ltd. All rights reserved.
587 600; fax: +31 475 587 592.
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Circulating sex hormones in sarcoidosis 2503exercise intolerance, diminished vitality and depressed mood were not related to
hypogonadism in these patients.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a heterogeneous multi-system disorder of
unknown aetiology with varying presentation of symptoms,
which often presents with bilateral hilar lymphadenopathy and
pulmonary infiltration.1 Respiratory and skeletal muscle func-
tion,2,3 exercise tolerance,3,4 symptoms of fatigue,3,5,6 vital-
ity3,7–10 and mood status3,7,10 have been shown to be worse in
comparison with healthy age-matched control subjects and
appear, at least in part, to be interrelated.3 These clinical
features can be the resultant of the disease itself, but can also
be secondary to persistent debilitating clinical complaints and
to the pharmacological treatment of sarcoidosis.1,3
Skeletal muscle weakness, fatigue and depression have
been shown to be partly related to low circulating (free)
testosterone in male outpatients with chronic diseases (i.e.
human immunodeficiency virus, chronic obstructive pulmon-
ary disease and depressive illness) and in aging healthy
men.11–16 Circulating testosterone concentrations appear
also to be low in male outpatients with sarcoidosis.17
Nonetheless, in the latter study a healthy control group
was lacking, patients were mostly African American and one
patient was thought to have neurosarcoidosis.17 Moreover,
the aforementioned relationships have never been studied
in male outpatients with sarcoidosis.
Although a direct comparison of circulating gonadotro-
phins concentrations of male sarcoidosis patients with those
of middle-aged healthy men has never been done, hypogo-
nadism in sarcoidosis can be of primary testicular dysfunc-
tion and/or a dysfunctioning hypothalamus-pituitary-
gonadotrophic axis.17,18 In addition, hypogonadism can be
caused by systemic inflammation15 or can be an incon-
venient side effect of the treatment with oral corticoster-
oids.19 The role of oral corticosteroids in the development of
hypogonadism, however, may be less prominent than
expected.15,17,20 A cross sectional study was therefore
undertaken to investigate two questions: Are circulating levels of follicle stimulating hormone
(FSH), luteinizing hormone (LH), testosterone, sex
hormone-binding globulin (SHGB) and free testosterone
of male outpatients with sarcoidosis significantly differ-
ent from those of healthy middle-aged men? What is the relationship between circulating (free)
testosterone concentrations and respiratory and skeletal
muscle function, 6-min walking distance, vitality, depres-
sion, systemic inflammation and mean daily dose of
corticosteroids in men with sarcoidosis?Material and methods
Study subjects and design
Forty-six consecutive male outpatients with sarcoidosis
visited the outpatient consultation of the Interstitial LungDiseases Unit of the University Hospital Gasthuisberg in
Leuven (Belgium) and were asked to participate in the
present study. Sixteen patients were reluctant to partici-
pate. Consequently, pulmonary function, respiratory and
skeletal muscle function, functional exercise capacity and
circulating levels of several hormones of the pituitary-
gonadal axis were determined in 30 consenting male
outpatients. Moreover, systemic inflammation, vitality,
depression and the seriousness of self-reported co-existing
comorbidities were determined as described below. Finally,
based on their chest radiograph, the sarcoidosis patients
were classified according to Scadding21: stage 0, no lung
involvement; stage 1, hilar enlargement alone; stage 2, hilar
enlargement plus interstitial lung disease; stage 3, inter-
stitial lung disease alone; and stage 4, lung fibrosis.
Sarcoidosis had been diagnosed a median of 3 years
previously (interquartile range, IQR: 3–9) according to the
latest ATS/ERS/WASOG statement on sarcoidosis.1 Fourteen
patients received oral corticosteroids in the 6-month period
before testing at a mean dose of 1.8–32.0 milligram of oral
methylprednisolone equivalents per day. The results of the
consenting outpatients with sarcoidosis were compared to
those of 26 healthy middle-aged men (Table 1) who were not
actively participating in sporting activities. Three students
of the authors’ faculty recruited the latter group among
relatives and friends.
The present design was in accordance with World Medical
Association declaration of Helsinki.22 The ethics committee
of the University Hospitals Leuven granted approval for the
present survey (local reference: ML2914). Except for one
African Belgian patient, all participants were of white
ethnic origin. All patients and control subjects gave oral and
written informed consent. Muscle function of seven sarcoi-
dosis patients3 and gonadal status of four middle-aged
control subjects15 have been published elsewhere. More-
over, for 14 male patients the present assessments were
obtained at baseline of the EXTRAS study.23Methods
Venous blood was drawn from supine participants between
08.30 and 09.00 A.M. before functional testing. Circulating
levels of FSH, LH, testosterone, SHBG and free testosterone
were determined or calculated as described previously by
Van Vliet and colleagues in an online supplement.15 In
addition, C-reactive protein (CRP), as a marker of systemic
inflammation, has been assessed.24
Forced expiratory volume in the first second, forced vital
capacity, total lung capacity and carbon monoxide transfer
factor were measured according to the guidelines of the
European Respiratory Society.25 In addition, maximal in-
spiratory mouth pressure sustained for 1 s, isometric quad-
riceps peak torque and the distance walked in 6min were
assessed as described previously by Spruit and colleagues in
an online supplement.3 In addition, reference values of
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Table 2 Physical function, vitality and depression.
Sarcoidosis
(n ¼ 30)
Healthy
(n ¼ 26)
p-
value
PImax, cmH2O 103.2 (4.5) 126.0 (5.4) 0.0019
PImax, % pred 84.8 (3.7) 103.1 (3.7) 0.0010
QPT, Nm 167.7 (8.6) 207.7 (8.9) 0.0023
QPT, % pred 73.4 (3.9) 92.3 (3.2) 0.0005
6 MWD, m 622 (25) 782 (23) 0.0001
6 MWD, % pred 78.3 (3.1) 98.1 (2.1) 0.0001
Vitality, points 40 (20–55) 80 (65–90) 0.0001
Depression,
points
8 (3–10) 0 (0–2) 0.0001
Values are expressed as mean (SE), except for vitality and
depression (median (IQR)). PImax ¼ maximal inspiratory
mouth pressure; QPT ¼ quadriceps peak torque; 6 MWD ¼ 6-
min walking distance; vitality scores can range from 0 points
(worst) to 100 points (optimal); depression scores can range
from 0 points (optimal) to 21 points (worst). n ¼ 29 out-
patients with sarcoidosis for vitality and depression.
Table 1 Demographics.
Sarcoidosis (n ¼ 30) Healthy (n ¼ 26) p-value
Age, years 43.6 (2.1) 43.6 (2.8) 0.9958
BMI, kg/m2 26.5 (0.8) 25.7 (0.6) 0.2968
FEVl, l 3.29 (0.18) 3.94 (0.16) 0.0104
FEVl, % pred 84.8 (3.8) 100.4 (2.8) 0.0020
FVC, l 4.44 (0.19) 5.13 (0.19) 0.0164
FVC, % pred 93.9 (3.3) 106.8 (2.8) 0.0062
TLC, l 6.29 (0.19) 7.25 (0.19) 0.0014
TLC, % pred 89.2 (2.4) 101.0 (2.5) 0.0034
TL,CO, mmol/min/Kpa 8.17 (0.38) 10.45 (0.40) 0.0003
TL,CO, % pred 75.8 (3.2) 95.4 (2.5) 0.0001
Smoking, c/f/n 5/3/22 6/1/19 0.5980
Pack years* 9 (5–18) 15(10–25) 0.1462
Scadding, I–IV 8/15/5/2 – –
Values are expressed as mean (SE), except for Scadding’s chest radiograph scores [21] and smoking status (c ¼ current; f ¼ former;
n ¼ never, absolute numbers), and for number of packyears and Charlson index [31] (median (IQR)). m ¼ meters; BMI ¼ body mass
index; kgm2 ¼ body weight per square height; FVC ¼ forced vital capacity; l ¼ liters; % predicted ¼ percent of the predicted value;
FEV1 ¼ forced expiratory volume in the first second; TLC ¼ total lung capacity; TL,CO ¼ transfer factor for carbon monoxide of the
lungs; *Packyears have been calculated for eight current or former smoking patients and seven current or former smoking control
subjects.
M.A. Spruit et al.2504Rochester and Arora,26 Decramer and colleagues27 and of
Trooster and colleagues28 have been used to calculate the
predicted values, respectively.
The domain vitality of the Medical Outcomes Study 36-
Item Short-Form Health Survey,29 and the domain depression
of the Hospital Anxiety and Depression Scale30 were used to
assess vitality and depression, respectively. Vitality scores
could range from 0 (worst) to 100 (optimal), while
depression scores could range from 0 (optimal) to 21
(worst).
Self-reported co-existing comorbidities have been classi-
fied using the Charlson index, which is a simple weighted
index that takes into account the number and the serious-
ness of comorbid disease.31
Statistical analyses
Results are presented as mean (standard error of the mean,
SE) or as median (IQR), as appropriate. A two-tailed
unpaired t-test (continuous), a Mann–Whitney U test or a
chi square test (binomial) was used to determine differences
between sarcoidosis patients and healthy control subjects.
Spearman rank correlation (rs) has been used to determine
relationships between circulating (free) testosterone con-
centrations and clinical outcomes in the patients. In
addition, a partial correlation was calculated between
testosterone and quadriceps peak torque (Newton-meters)
after controlling for age, body weight and height. A priori, a
two-sided level of significance was set at pp0.05.32
Results
Characteristics
Patients with sarcoidosis had a statistically significant worse
pulmonary function (Table 1), respiratory and skeletalmuscle function and functional exercise capacity than
healthy peers (Table 2). In addition, patients had worse
median scores for vitality and depression (Table 2), and
increased circulating CRP concentrations (Table 3). Age,
body mass index and smoking status were comparable
between the two groups (Table 1).Hormones of the pituitary–gonadal axis
Median circulating gonadotrophins concentrations were
similar between patients and healthy control subjects. In
addition, male outpatients with sarcoidosis had significantly
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Figure. 1 Upper panel: Testosterone (expressed as ng/dl)
versus quadriceps peak torque (expressed as a % of the
predicted value) in male outpatients with sarcoidosis. Lower
panel: Testosterone (expressed as ng/dl) versus vitality (ex-
pressed in arbitrary units: points) in male outpatients with
sarcoidosis.
Table 3 Systemic inflammation and gonadal status.
Sarcoidosis (n ¼ 30) Healthy (n ¼ 26) p-value
CRP, mg/l 1.8 (1.0–4.1) 1.0 (1.0–1.0) 0.0086
FSH, mIU/ml 3.6 (2.7–6.6) 4.3 (3.1–6.3) 0.5818
LH, mIU/ml 2.9 (2.4–3.6) 3.4 (2.5–4.9) 0.1598
TST, ng/dl 321 (245–404) 426 (375–475) 0.0014
SHBG, mg/dl 0.81 (0.58–1.08) 1.02 (0.79–1.33) 0.0515
Free TST, ng/dl 7.32 (5.48–8.72) 9.25 (7.54–9.87) 0.0062
Values are expressed as median (IQR). FSH ¼ follicle stimulating hormone; LH ¼ luteinizing hormone; TST ¼ testosterone; SHBG ¼ sex
hormone-binding globulin.
Circulating sex hormones in sarcoidosis 2505lower median circulating levels of testosterone and free
testosterone than healthy middle-aged men, while circulat-
ing SHBG concentrations tended to be lower in the patients
(Table 3).
Age was related to circulating levels of SHBG (rs ¼ 0.56,
p ¼ 0.0014) and free testosterone (rs ¼ 0.53, p ¼
0.0025) in the patients with sarcoidosis. In addition,
circulating testosterone concentrations were significantly
related to circulating levels of SHBG (rs ¼ 0.63, p ¼
0.0002) and free testosterone (rs ¼ 0.81, p ¼ 0.0001).
Oral corticosteroids and sex hormones
Median circulating levels of testosterone and free testoster-
one did not differ between patients who used oral
corticosteroids in the past 6 months (n ¼ 14, 284 ng/dl
(186–406); and 7.32 ng/dl (4.70–8.95), respectively) and
those who did not (n ¼ 16, 345 ng/dl (266–401), p ¼
0.8843; and 7.32 ng/dl (6.15–8.42), p ¼ 0.3286, respec-
tively). In addition, patients who did not use oral corticos-
teroids in the past 6 months had significantly lower
circulating levels of testosterone (p ¼ 0.0111) and free
testosterone (p ¼ 0.0156) than healthy control subjects.
Co-existing morbidities and sex hormones
Four patients reported one co-existing morbidity on the
Charlson comorbity index: diabetes mellitus type 2 (n ¼ 2);
congestive heart failure (n ¼ 1); and mild liver disease
(n ¼ 1). None of the control subjects reported co-existing
morbidities. Consequently, self-reported co-existing mor-
bidities were more prevalent in the sarcoidosis patients
compared to healthy peers (w2: p ¼ 0.049). Patients without
self-reported co-existing morbidities had significantly lower
median circulating levels of testosterone (316 ng/dl
(245–406), p ¼ 0.0033) and free testosterone (7.42 ng/dl
(5.48–8.95), p ¼ 0.0275) than healthy control subjects.
Clinical outcomes and sex hormones
Reduced circulating (free) testosterone concentrations were
not significantly related to body mass index, pack years,
maximal inspiratory mouth pressure sustained for 1 s,
quadriceps muscle force (upper panel of Figure 1),
functional exercise intolerance, diminished vitality (lower
panel of Figure 1), depressed mood or systemic inflamma-
tion in male outpatients with sarcoidosis (Table 4). Inaddition, no significant relationship has been found
between quadriceps peak torque and circulating testoster-
one levels, after controlling for age, body weight and height
(r ¼ 0.063, p ¼ 0.754).Discussion
The present study has two novel observations: (1) male
outpatients with sarcoidosis had lower median cir-
culating (free) testosterone concentrations than healthy
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Table 4 Spearman correlation coefficients between
testosterone status and clinical outcomes in male out-
patients with sarcoidosis.
Testosterone
(ng/dl)
Free testosterone
(ng/dl)
Age, years 0.08 0.53
BMI, kg/m2 0.17 0.20
FVC, % pred 0.17 0.20
TL,CO, % pred 0.02 0.04
Pack years 0.19 0.14
PImax, % pred 0.09 0.05
QPT, % pred 0.02 0.09
6MWD, % pred 0.04 0.16
Vitality, points 0.02 0.14
Depression, points 0.09 0.25
CRP, mg/l 0.15 0.30
m ¼ meters; BMI ¼ body mass index; kgm2 ¼ body weight
per square height; FVC ¼ forced vital capacity; % predic-
ted ¼ percent of the predicted value; TL,CO ¼ transfer
factor for carbon monoxide of the lungs; PImax ¼ maximal
inspiratory mouth pressure; QPT ¼ quadriceps peak torque;
6MWD ¼ 6-min walking distance; n ¼ 29 outpatients with
sarcoidosis for vitality and depression.
p ¼ 0.0025.
M.A. Spruit et al.2506middle-aged men, without changes in median circulating
FSH and LH concentrations; and (2) a statistically significant
worse respiratory and skeletal muscle function, functional
exercise intolerance, diminished vitality and depressed
mood were not related to the reduced circulating (free)
testosterone concentrations in male outpatients with
sarcoidosis.Hypogonadism
Male outpatients with sarcoidosis had reduced median
circulating testosterone concentrations (Table 3). Compar-
able findings have been found in African American out-
patients with sarcoidosis.17 Nevertheless, the present study
is the first to include an age-matched control group. In
addition, all except one patient were of white ethnic origin.
In the present study, 14 patients (46.7%) had circulating
testosterone concentrations below the lower limit of normal
(p300 ng/dl).15 Subsequently, a compensatory reduction in
circulating SHBG concentrations in the patients (p ¼
0.0515, Table 3) has been found to increase the circulating
free testosterone concentrations. The number of patients
(n ¼ 7, 23.3%) with low circulating free testosterone
concentrations (p5 ng/dl)15 was lower than the number of
patients with low circulating testosterone concentrations.
However, patients’ median circulating free testosterone
concentrations still remained below the values of the
healthy control subjects (Table 3).
Median circulating testosterone concentrations were not
different between patients who used oral corticosteroids
and those who did not. This is in line with previous findings
in patients with sarcoidosis17 or chronic obstructive pul-monary disease (14;19). Median circulating testosterone
concentrations were still significantly lower as compared to
healthy control subjects after excluding four patients with
self-reported co-existing comorbidities. In addition, circu-
lating testosterone concentrations were not related to the
number of pack years or circulating CRP concentrations
(Table 4). Therefore, other factors may have contributed to
the presence of hypogonadism in male outpatients with
sarcoidosis. Indeed, absent increases in circulating levels of
FSH (o8.1mUI/ml)15 and LH (o5.3mUI/ml)15 have been
found in 12 (85.7%) and 13 (92.9%) out of 14 hypogonadal
outpatients with sarcoidosis, respectively. These findings
point strongly towards a hypofunctioning of the hypothala-
mus–pituitary–gonadal axis in male outpatients with sarcoi-
dosis.18 In fact, Adler and colleagues reported also
hypogonadotrophic-hypogonadism in 85.7% of the hypogo-
nadal male outpatients with sarcoidosis.17 However, a
hypofunctioning of the hypothalamus–pituitary–gonadal axis
in combination with a primary testicular dysfunction18
cannot be excluded based on earlier17 or current results.
Quadriceps muscle function
Recently, the present authors hypothesized that physical
deconditioning, at least in part, can be responsible for
quadriceps muscle weakness in sarcoidosis.3 The lack of a
significant relationship between reduced circulating (free)
testosterone concentrations and quadriceps muscle weak-
ness in male outpatients with sarcoidosis (even after
controlling for age, body weight and height) is in favor of
this hypothesis. In fact, the relationship between quadriceps
muscle weakness and hypogonadism does not appear to be
straightforward,33 whereas its relationship with physical
inactivity is well established.34
Recently, the possible underlying factors of a reduced
muscle function in patients with sarcoidosis have been
discussed in depth.35 To date, the presence of the disease in
skeletal muscles of patients with sarcoidosis cannot be ruled
out.36 In addition, effects of oral corticosteroids on muscle
function may not be underestimated. Previously, a signifi-
cant inverse relationship has been found between the mean
daily dose of oral corticosteroids and quadriceps peak
torque in the patients who received oral corticosteroids in
the 6-month period preceding the tests.3 In addition, an a
posteriori analysis of variance revealed a worse quadriceps
muscle function in male outpatients with sarcoidosis who
used oral corticosteroids in the past 6 months as compared
to those who did not and healthy middle-aged control
subjects (upper left panel of Figure 2). Noteworthy, patients
who did not use oral corticosteroids were still significantly
weaker as compared to healthy control subjects. Addition-
ally, similar findings were found for the 6-min walking
distance (lower left panel of Figure 2).
Respiratory muscle function
Weakened inspiratory muscles3,6,37 may contribute substan-
tially to the sensation of dyspnea during day-to-day
activities in outpatients with sarcoidosis. In fact, reduced
maximal inspiratory mouth pressure has been related to
worse scores for dyspnea on the modified British Medical
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Figure. 2 Upper left panel: Mean (SE) quadriceps peak torque (QPT, expressed as a % of the predicted value) of healthy control
subjects, outpatients with sarcoidosis who did not use oral corticosteroids in the past 6 months (MDD ¼ 0), and outpatients with
sarcoidosis with a mean daily dose of corticosteroids of 4mg per day (IQR: 2–12) in the past 6 months (MDD4 0). *:po0.05 versus MDD
4 0; z:po0.05 versus MDD ¼ 0. Lower left panel: Mean (SE) 6-min walking distance (6MWD, expressed as a % of the predicted value)
of healthy control subjects, outpatients with sarcoidosis who did not use oral corticosteroids in the past 6 months (MDD ¼ 0), and
outpatients with sarcoidosis with a mean daily dose of corticosteroids of 4mg per day (IQR: 2–12) in the past 6 months (MDD 4 0).
*:po0.05 versus MDD40; z:po0.05 versus MDD ¼ 0. Upper right panel: Mean (SE) maximal inspiratory mouth pressure (PImax,
expressed as a % of the predicted value) of healthy control subjects, outpatients with sarcoidosis who did not use oral corticosteroids
in the past 6 months (MDD ¼ 0), and outpatients with sarcoidosis with a mean daily dose of corticosteroids of 4mg per day (IQR: 2–12)
in the past 6 months (MDD40). *:po0.05 versus MDD40.
Circulating sex hormones in sarcoidosis 2507Research Council scale.37 Moreover, decreased respiratory
muscle endurance time has been shown to be inversely
related to subscales mobility and body movement of the
Sickness Impact Profile in outpatients with sarcoidosis,
irrespective of the pulmonary function impairment.6
To date, the underlying causes of respiratory muscle
weakness in male outpatients with sarcoidosis remain
unknown. Indeed, a statistically significant reduction in
inspiratory muscle strength did not appear to be caused by a
hypogonadal status (Table 4), disuse or systemic inflamma-
tion.3 Moreover, oral corticosteroids did not appear to affect
maximal inspiratory mouth pressure.3,6,38 Then again, the
mean daily dose of oral corticosteroids has been shown to be
independently responsible for 32% and 54% of the variance in
maximal inspiratory mouth pressure in patients with chronic
obstructive pulmonary disease27 or cystic fibrosis,39 respec-
tively. In the present study, an a posteriori analysis of
variance showed only a worse inspiratory mouth pressure inthe patients who used oral corticosteroids in the past 6
months compared to those who did not and healthy middle-
aged control subjects (upper right panel of Figure 2).
Measurement of maximal inspiratory mouth pressure is by
far the most widely used test for assessing the inspiratory
muscle strength.40 In fact, the mean PImax sustained for
1 s (84.8% of predicted) was statistically significant worse
compared to healthy age-matched control subjects (Table 2)
and has been shown to be comparable to recent results of
Kabitz and colleagues (85.6% of predicted).2 Nevertheless,
the latter authors have not found a statistically significant
difference between nonvolitional inspiratory muscle
strength between patients with sarcoidosis and healthy
control subjects.2 This may imply that on average inspira-
tory muscle strength is not different using effort-indepen-
dent techniques. Unfortunately, the present authors did not
have access to a magnetic stimulator at the time of the
present study.
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M.A. Spruit et al.2508Vitality and depression
Diminished vitality and increased depression have been
reported in patients with sarcoidosis compared to healthy
peers3,7–10. These persistent clinical complaints may, at
least in part, be explained by a hypogonadal sta-
tus.11,12–14,16,41 Nonetheless, reduced circulating (free)
testosterone concentrations were not related to diminished
vitality and depressed mood in the present male outpatients
with sarcoidosis (Figure 1 and Table 3). Other underlying
factors (i.e. physical deconditioning) may therefore be
partially responsible for the reduced vitality and increased
depression in sarcoidosis.3 Actually, the involvement of
physical deconditioning in diminished vitality and depressed
mood scores may be indicated by the significant improve-
ment in scores following an exercise-training program in
outpatients with sarcoidosis.42–44 This, however, has never
been studied in sarcoidosis.Methodological and statistical considerations
The present study has clear limitations. Only circulating CRP
concentrations have been studied as a marker of systemic
inflammation, while specific pro-inflammatory cytokines are
thought to play a role in the development and/or main-
tenance of hypogonadism.45 Nevertheless, circulating levels
of interleukin-6, interleukin-8, tumor necrosis factor alpha
and its soluble receptors were not or only weakly related to
the reduced circulating (free) testosterone concentrations
in male outpatients with clinically stable but advanced
chronic obstructive pulmonary disease.15,46 Whether and to
what extent systemic markers of disease severity (e.g.
serum levels of soluble interleukin-2 receptor, angiotensin
converting enzyme and neopterin) may somehow be
partially related to hypogonadism in male sarcoidosis
patients remains currently unknown.47,48
The presence of sarcoidosis at the scrotum and/or
pituitary gland has not been ruled out and may therefore,
at least in part, be responsible for the observed hypogonad-
ism in male outpatients with sarcoidosis.49 Nevertheless,
none of the patients complained spontaneously
about recurrent fainting or dysesthesia50 at the time of
the study. Additionally, these types of sarcoidosis are very
rare.51,52
Only male subjects have been studied in the present
study, which appears to be understandable. Then again, it
may be meaningful to perform a similar study in female
sarcoidosis outpatients.53
The external validity of the present findings is limited to
male outpatients with sarcoidosis of white ethnic origin54
and should therefore be reproduced in a larger sample
with ethnically diverse sarcoidosis patients.55 Indeed,
the present results are rather hypotheses generating
than definitive.
The present sample may have been too small to find
significant differences in median circulating testosterone
concentrations between patients who had been using oral
corticosteroids (284 ng/dl) and those who did not (345 ng/dl,
p ¼ 0.8843). Then again, median circulating free testoster-
one concentrations were identical (7.32 ng/dl). In addition,
Adler and colleagues also did not find an effect of oralcorticosteroids on gonadal status in male patients with
sarcoidosis.17
Statistically significant differences between groups need
to be interpreted in the light of the number of comparisons
that were made in the present study. Nonetheless, the
current statistical procedures have been used to test pre-
defined hypotheses. Moreover, ‘Bonferoni adjustments are
at best, unnecessary and, at worst, deleterious to sound
statistical inference’.56 Finally, due to the cross-sectional
design, it is impossible to work out the temporal sequence of
the present clinical outcomes.57
Future directions
To date, the clinical relevance of hypogonadism in male
outpatients with sarcoidosis remains unknown. In particular,
a lack of significant relationships with the current clinical
outcomes raises questions. It may therefore be too early to
consider randomized controlled trials on the effects of
testosterone supplements in highly selected hypogonadal
male outpatients with sarcoidosis. Then again, hypogonad-
ism can be one of the underlying factors causing erectile
dysfunction in middle-aged men58 and may therefore be
worthwhile to study in future studies in middle-aged male
patients with sarcoidosis. Unfortunately, erectile dysfunc-
tion has not been included as an outcome in the present
study. In fact, erectile dysfunction in sarcoidosis has only
been reported in several case-reports of patients with
neurosarcoidosis or with sarcoidosis in the scrotum.50,59,60
Conclusions
A worse respiratory and quadriceps femoris muscle function,
exercise intolerance, diminished vitality and depressed
mood were not related to the hypogonadal status in men
with sarcoidosis. Therefore, the clinical relevance of
hypogonadism warrants further studies in men with sarcoi-
dosis. Nevertheless, physicians still have to be aware that
hypogonadism can be one of the underlying causes of one of
the aforementioned clinical symptoms in individual male
patients with sarcoidosis. Finally, oral corticosteroids may,
at least in part, affect inspiratory muscle force, quadriceps
muscle force and 6-min walking distance in male outpatients
with sarcoidosis.
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